drugset
drugset / Trial / NCT05355129

A Phase 1 Study of TT-00920 in Healthy Subjects

NCT05355129 ↗

Phase 1 Completed 30 enrolled TransThera Sciences (Nanjing), Inc.
RandomizedSequentialTriple-blindTreatment

Summary

This is a double-blind, randomized, placebo-controlled, ascending single dose and multiple dose escalation study of TT-00920 in healthy subjects.

Timeline

Start
2021-11-03
Primary completion
2022-06-06
Completion
2022-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TT-00920 Unknown — —

Indications

No indication recorded.